CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression
Huifeng Gao, Chien‐shan Cheng, Jian Tang, Ye Li, Hao Chen, Zhiqiang Meng, Zhen Chen, Lianyu Chen
Abstract
treatment of CXCL9 directly led to the suppression of the proliferation, activation, and secretion of anti-tumour cytokines of isolated CD8+ T cells. Inhibition of STAT3 recovered the CXCL9-inhibited proliferation, activation, and secretion of anti-tumour cytokines of CD8+ T cells. Our study indicates CXCL9 as a potential target of immunotherapy in PAAD treatment by regulating the CD8+ T lymphocytes in the tumour microenvironment.
Topics & Concepts
CXCL9Cytotoxic T cellChemokineCXCL10Cancer researchCXCL11ImmunologyChemistryBiologyImmune systemIn vitroBiochemistryPancreatic and Hepatic Oncology ResearchCancer Immunotherapy and BiomarkersImmune Cell Function and Interaction